531 related articles for article (PubMed ID: 22197931)
1. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
Nikolaev SI; Rimoldi D; Iseli C; Valsesia A; Robyr D; Gehrig C; Harshman K; Guipponi M; Bukach O; Zoete V; Michielin O; Muehlethaler K; Speiser D; Beckmann JS; Xenarios I; Halazonetis TD; Jongeneel CV; Stevenson BJ; Antonarakis SE
Nat Genet; 2011 Dec; 44(2):133-9. PubMed ID: 22197931
[TBL] [Abstract][Full Text] [Related]
2. MEK1 mutations confer resistance to MEK and B-RAF inhibition.
Emery CM; Vijayendran KG; Zipser MC; Sawyer AM; Niu L; Kim JJ; Hatton C; Chopra R; Oberholzer PA; Karpova MB; MacConaill LE; Zhang J; Gray NS; Sellers WR; Dummer R; Garraway LA
Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20411-6. PubMed ID: 19915144
[TBL] [Abstract][Full Text] [Related]
3. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
Long GV; Fung C; Menzies AM; Pupo GM; Carlino MS; Hyman J; Shahheydari H; Tembe V; Thompson JF; Saw RP; Howle J; Hayward NK; Johansson P; Scolyer RA; Kefford RF; Rizos H
Nat Commun; 2014 Dec; 5():5694. PubMed ID: 25452114
[TBL] [Abstract][Full Text] [Related]
4. Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma.
Richmond CS; Vallatharasu Y; Deviley JA; Vos CR; Parsons BM; Kenny PA
Exp Mol Pathol; 2019 Oct; 110():104260. PubMed ID: 31082388
[TBL] [Abstract][Full Text] [Related]
5. Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.
Estep AL; Palmer C; McCormick F; Rauen KA
PLoS One; 2007 Dec; 2(12):e1279. PubMed ID: 18060073
[TBL] [Abstract][Full Text] [Related]
6. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
[TBL] [Abstract][Full Text] [Related]
7. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Krauthammer M; Kong Y; Ha BH; Evans P; Bacchiocchi A; McCusker JP; Cheng E; Davis MJ; Goh G; Choi M; Ariyan S; Narayan D; Dutton-Regester K; Capatana A; Holman EC; Bosenberg M; Sznol M; Kluger HM; Brash DE; Stern DF; Materin MA; Lo RS; Mane S; Ma S; Kidd KK; Hayward NK; Lifton RP; Schlessinger J; Boggon TJ; Halaban R
Nat Genet; 2012 Sep; 44(9):1006-14. PubMed ID: 22842228
[TBL] [Abstract][Full Text] [Related]
8. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
Kim KB; Kefford R; Pavlick AC; Infante JR; Ribas A; Sosman JA; Fecher LA; Millward M; McArthur GA; Hwu P; Gonzalez R; Ott PA; Long GV; Gardner OS; Ouellet D; Xu Y; DeMarini DJ; Le NT; Patel K; Lewis KD
J Clin Oncol; 2013 Feb; 31(4):482-9. PubMed ID: 23248257
[TBL] [Abstract][Full Text] [Related]
10. Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome.
Rodriguez-Viciana P; Rauen KA
Methods Enzymol; 2008; 438():277-89. PubMed ID: 18413255
[TBL] [Abstract][Full Text] [Related]
11. Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome.
Narumi Y; Aoki Y; Niihori T; Neri G; Cavé H; Verloes A; Nava C; Kavamura MI; Okamoto N; Kurosawa K; Hennekam RC; Wilson LC; Gillessen-Kaesbach G; Wieczorek D; Lapunzina P; Ohashi H; Makita Y; Kondo I; Tsuchiya S; Ito E; Sameshima K; Kato K; Kure S; Matsubara Y
Am J Med Genet A; 2007 Apr; 143A(8):799-807. PubMed ID: 17366577
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of MEK inhibition in patients with histiocytic neoplasms.
Diamond EL; Durham BH; Ulaner GA; Drill E; Buthorn J; Ki M; Bitner L; Cho H; Young RJ; Francis JH; Rampal R; Lacouture M; Brody LA; Ozkaya N; Dogan A; Rosen N; Iasonos A; Abdel-Wahab O; Hyman DM
Nature; 2019 Mar; 567(7749):521-524. PubMed ID: 30867592
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
[TBL] [Abstract][Full Text] [Related]
14. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.
Shi H; Moriceau G; Kong X; Koya RC; Nazarian R; Pupo GM; Bacchiocchi A; Dahlman KB; Chmielowski B; Sosman JA; Halaban R; Kefford RF; Long GV; Ribas A; Lo RS
Cancer Discov; 2012 May; 2(5):414-24. PubMed ID: 22588879
[TBL] [Abstract][Full Text] [Related]
15. Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma.
Wong SQ; Behren A; Mar VJ; Woods K; Li J; Martin C; Sheppard KE; Wolfe R; Kelly J; Cebon J; Dobrovic A; McArthur GA
Oncotarget; 2015 Jan; 6(2):1115-27. PubMed ID: 25544760
[TBL] [Abstract][Full Text] [Related]
16. Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations.
Dentici ML; Sarkozy A; Pantaleoni F; Carta C; Lepri F; Ferese R; Cordeddu V; Martinelli S; Briuglia S; Digilio MC; Zampino G; Tartaglia M; Dallapiccola B
Eur J Hum Genet; 2009 Jun; 17(6):733-40. PubMed ID: 19156172
[TBL] [Abstract][Full Text] [Related]
17. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
18. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
Emery CM; Monaco KA; Wang P; Balak M; Freeman A; Meltzer J; Delach SM; Rakiec D; Ruddy DA; Korn JM; Haling J; Acker MG; Caponigro G
Mol Cancer Res; 2017 Oct; 15(10):1431-1444. PubMed ID: 28655712
[TBL] [Abstract][Full Text] [Related]
19. Novel genetic alteration in congenital melanocytic nevus: MAP2K1 germline mutation with BRAF somatic mutation.
Zou Y; Sun Y; Zeng X; Liu Y; Cen Q; Gu H; Lin X; Cai R; Chen H
Hereditas; 2020 Aug; 157(1):35. PubMed ID: 32847629
[TBL] [Abstract][Full Text] [Related]
20. A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244).
Boers-Sonderen MJ; Desar IM; Blokx W; Timmer-Bonte JN; van Herpen CM
Anticancer Drugs; 2012 Aug; 23(7):761-4. PubMed ID: 22293660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
